Search

Priothera Closes $35M USD Series A Private Placement


Priothera Closes $35M USD Series A Private Placement to Develop Highly Promising Therapies for Acute Myeloid Leukemia.


DUBLIN, Oct. 12, 2020 -- Priothera Limited, a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies, today announced that it has successfully closed a Series A financing round of €30 million led by Fountain Healthcare Partners with participation from co-lead investor HealthCap and funds managed by Tekla Capital Management, LLC as well as EarlyBird Venture Capital.

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogenic hematopoietic stem cell transplantation (HSCT) for treating AML. Priothera expects to generate further randomized clinical data in high risk AML patients with this Series A funding round.

Mocravimod has already been extensively tested in multiple immunologic indications and has shown survival benefit in an early clinical study evaluating acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients undergoing hematopoietic stem cell transplantation (HSCT). Priothera acquired mocravimod from KYORIN Pharmaceutical Co., Ltd.

Following the closing of the financing, Florent Gros (Priothera's Co-Founder and CEO), Dr. Dhaval Patel (Priothera's Co-Founder and CSO at UCB), Dr. Manus Rogan (Fountain Healthcare Partners Co-Founder and Managing Director), Dr. Mårten Steen (Partner at HealthCap), Dr. Henry Skinner (Senior Vice President at Tekla Capital Management, LLC) and Lionel Carnot (Partner at EarlyBird Venture Capital), have joined the Board of Directors.

Fountain Healthcare Partners

Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain's main office is in Dublin, Ireland, with a second office in New York. fh-partners.com

HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. The investment strategy focuses on diseases with high-unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Over the years HealthCap has backed and built more than 100 companies, taken more than 40 companies public and done numerous trade sales.

Tekla

Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts and is the investment adviser for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies.

Earlybird

Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. Earlybird manages separate funds focussing on digital technologies in Eastern and Western Europe as well as healthcare across Europe. With over EUR 1 billion under management, seven IPOs and 24 trade sales, Earlybird is one of the most successful venture capital firms in Europe.

0 views

Private Placement Markets, LLC ("Private Placement Markets"), a Delaware Limited Liability Company, is a Private Placement Debt Underwriter, Private Debt Loan Servicing Agent and an Investor Relations Firm. The Private Placement Markets do not offer, and do not offer to provide any broker dealer or market maker services (through broker dealers and market makers are trading members of Private Placement Markets, trading both for their own accounts and/or client's accounts). The Members of the Private Placement Markets operate this website (referred to as the “Website”). By accessing this Website and any pages thereof, you agree to be bound by its Terms of Use and Privacy Policy. Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections may not reflect actual future performance. The Private Placement Markets, and/or any of its members, do not provide financial planning services. The Private Placement Markets, and/or any of its members, do not provide tax advice and do not represent in any manner that any of the outcomes described herein will result in any particular tax consequence. The Private Placement Markets Participants should conduct their own due diligence, not rely on the financial assumptions or estimates displayed on this Website, and are encouraged to consult with their own financial advisor, attorney, accountant, and any other professional that can help you / them to understand and assess the risks associated with any Private Placement Debt Lending / Investment Opportunity.

Access to Investment / Lending pages and access to all Due Diligence pages is strictly limited to: Select Members of Family Offices, SEC or FINRA Registered Investment Advisors or Broker Dealers, Hedge Funds, Life Insurance Asset Managers, Certain Accredited Investors (under the advisement of a FINRA Registered Financial Advisor or Broker Dealer), Pension Fund Managers, Foundations, Endowments, Certain Venture Capital Firms, Real Estate Private Equity Firms and Real Estate Investment Trust Asset Managers. No Member of the Private Placement Markets is associated with any CrowdFunding Sites, and no member of the Private Placement Markets provides any CrowdFunding Services.  

 

© 2019 by Private Placement Markets  and Steve Muehler